EQL | IVE | EQL / IVE | |
Gain YTD | 3.441 | 2.373 | 145% |
Net Assets | 420M | 35.6B | 1% |
Total Expense Ratio | N/A | N/A | - |
Turnover | 14.00 | 29.00 | 48% |
Yield | 1.79 | 1.62 | 111% |
Fund Existence | 16 years | 25 years | - |
EQL | IVE | |
---|---|---|
RSI ODDS (%) | N/A | 16 days ago86% |
Stochastic ODDS (%) | 16 days ago90% | 16 days ago88% |
Momentum ODDS (%) | 16 days ago73% | 16 days ago76% |
MACD ODDS (%) | N/A | N/A |
TrendWeek ODDS (%) | 16 days ago86% | 16 days ago84% |
TrendMonth ODDS (%) | 16 days ago71% | 16 days ago77% |
Advances ODDS (%) | 29 days ago85% | 18 days ago82% |
Declines ODDS (%) | 17 days ago71% | 25 days ago74% |
BollingerBands ODDS (%) | N/A | N/A |
Aroon ODDS (%) | 16 days ago68% | 16 days ago83% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
JHID | 28.64 | 0.81 | +2.91% |
JHancock International High Dividend ETF | |||
UMAY | 34.09 | 0.05 | +0.16% |
Innovator U.S. Equity Ultra BffrETF™-May | |||
PFEB | 37.07 | 0.05 | +0.14% |
Innovator US Equity Power Bffr ETF™ Feb | |||
TOTL | 39.41 | -0.04 | -0.10% |
SPDR® DoubleLine® Total Return Tact ETF | |||
XPH | 44.50 | -0.20 | -0.45% |
SPDR® S&P Pharmaceuticals ETF |